| Abstrakt: |
A recent study conducted at the Kempegowda Institute of Medical Sciences in Karnataka, India, has found that carbamylated haemoglobin can be used as a marker to differentiate between acute kidney injury (AKI) and chronic kidney disease (CKD). The study involved 60 patients, with 30 each diagnosed with CKD and AKI. The levels of carbamylated haemoglobin were significantly higher in the CKD group compared to the AKI group, indicating that a value above 100 mgVH/g is diagnostic of CKD, while a value below 100 mgVH/g is diagnostic of AKI. This finding suggests that carbamylated haemoglobin could be a useful biomarker for distinguishing between AKI and CKD. [Extracted from the article] |
